Carmot Therapeutics
Berkeley, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $310M
Overview
A biotech using its Chemotype Evolution platform to discover small molecule drugs for metabolic diseases and cancer.
Metabolic DiseaseOncology
Technology Platform
The Chemotype Evolution platform is a proprietary drug discovery technology that rapidly identifies and optimizes small molecule therapeutics for difficult-to-drug targets like GPCRs.
Funding History
2Total raised:$310M
Series D$150M
Series C$160M
Opportunities
Potential for partnership or acquisition based on positive Phase 2 data for its metabolic candidates and expansion of its oncology pipeline.
Risk Factors
Clinical trial failures in its lead metabolic programs and intense competition in the incretin space could significantly impact valuation.
Competitive Landscape
Operates in the highly competitive obesity and diabetes drug market, facing off against giants with approved GLP-1 drugs, while its platform offers a differentiated discovery approach.